 Isoniazid
"Isoniazid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
| Descriptor ID |
D007538
|
| MeSH Number(s) |
D02.442.436 D03.066.349.410 D03.383.725.394.582
|
| Concept/Terms |
Isoniazid- Isoniazid
- Isonicotinic Acid Hydrazide
- Hydrazide, Isonicotinic Acid
Phthivazide- Phthivazide
- Phthivazid
- Isonicotinic Acid Vanillylidenehydrazide
- Acid Vanillylidenehydrazide, Isonicotinic
- Vanillylidenehydrazide, Isonicotinic Acid
- Ftivazide
|
Below are MeSH descriptors whose meaning is more general than "Isoniazid".
Below are MeSH descriptors whose meaning is more specific than "Isoniazid".
This graph shows the total number of publications written about "Isoniazid" by people in this website by year, and whether "Isoniazid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2002 | 2 | 1 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 0 | 2 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 4 | 1 | 5 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 2 | 3 | | 2021 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Isoniazid" by people in Profiles.
-
Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis. 2021 11 02; 73(9):e3555-e3562.
-
Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467.
-
Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0170521.
-
Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Theron G, Montepiedra G, Aaron L, McCarthy K, Chakhtoura N, Jean-Philippe P, Zimmer B, Loftis AJ, Chipato T, Nematadzira T, Nyati M, Onyango-Makumbi C, Masheto G, Ngocho J, Tongprasert F, Patil S, Lespinasse D, Weinberg A, Gupta A. Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):e784-e790.
-
Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2021 04; 109(4):1034-1044.
-
Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 08 22; 71(5):1320-1323.
-
Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 07 15; 202(2):305-306.
-
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019 10 03; 381(14):1333-1346.
-
Moon SM, Choe J, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med. 2019 03; 148:37-42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|